Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mayte Gil Candel"'
Autor:
Aaron Puplà Bartoll, Mª Dolores Bellés Medall, Ignacio Pérez Catalán, Celia Roig Martí, Julia Bodega Azuara, Mayte Gil Candel, Vicent Esteve López, Raúl Ferrando Piqueres
Publikováno v:
Revista Española de Quimioterapia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d67bf07b1fa97d64096d8b4c7dc58d1a
https://doi.org/10.37201/req/147.2022
https://doi.org/10.37201/req/147.2022
Autor:
Mayte Gil-Candel, Antonio Solana-Altabella, Esther Vicente-Escrig, Aarón Puplá-Bartoll, Julia Bodega Azuara, Pablo Pérez-Huertas, Raul Ferrando Piqueres
Publikováno v:
European Journal of Hospital Pharmacy. 30:107-112
This study aimed to describe the actions taken to implement a telepharmacy programme with home medication dispensing and informed delivery in an outpatient pharmaceutical care unit of a tertiary hospital, where approximately 5000 patients are treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b2483e18d42fdef52b264171619e8a5
https://doi.org/10.1136/ejhpharm-2021-003194
https://doi.org/10.1136/ejhpharm-2021-003194
Autor:
María Onteniente-Candela, Elena Urbieta-Sanz, Juan José Gascón-Cánovas, Lorena Rentero-Redondo, Mayte Gil-Candel, Carles Iniesta-Navalón
Publikováno v:
International Journal of Clinical Pharmacy. 42:500-507
Background Conventional therapy of inflammatory bowel disease with traditional immunosuppressant medication is increasingly being replaced by biological agents. However, the response to these biological agents may be lost over time, with discontinuat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::561a7845039038b7c68fa73a389907cf
https://doi.org/10.1007/s11096-020-00978-6
https://doi.org/10.1007/s11096-020-00978-6
Autor:
Isabel Nicolás de Prado, Elena Urbieta Sanz, Carles Iniesta Navalón, Rosa Gómez Espín, Juan José Gascón Cánovas, Mayte Gil Candel
Publikováno v:
Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 112(5)
Introduction: previous studies have shown that higher infliximab trough levels are associated with favorable short-term and long-term therapeutic outcomes in inflammatory bowel disease. There is a need to determine which patients could benefit from p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89f9dfcccdb405f8aa9dd46d814d8bec
https://pubmed.ncbi.nlm.nih.gov/32338010
https://pubmed.ncbi.nlm.nih.gov/32338010
Autor:
Mayte Gil Candel, Rosa Gómez Espín, Lorena Rentero Redondo, Marta González Carrión, Carles Iniesta Navalón, Isabel Nicolás de Prado
Publikováno v:
Revista Española de Enfermedades Digestivas.
Introduction numerous studies have shown a positive correlation between serum biologic drug concentrations and favorable therapeutic outcomes during the induction and maintenance period in patients with Crohn's disease (CD). To our knowledge, only a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6979fac7c9d00ecf6f2c0a2e1562e37b
https://doi.org/10.17235/reed.2020.7124/2020
https://doi.org/10.17235/reed.2020.7124/2020
Autor:
Isabel Nicolás de Prado, Carles Iniesta Navalón, Juan José Gascón Cánovas, Rosa Gómez Espín, Elena Urbieta Sanz, Mayte Gil Candel, Lorena Rentero Redondo
Publikováno v:
Revista Española de Enfermedades Digestivas. 112
Introduction: infliximab is used in inflammatory bowel disease, which has a great inter-individual pharmacokinetic variability. Thus, it is necessary to individualize the therapy in many cases. The main objective of our study was to compare two metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9c092a1ef7e88b7fd2ff024ed7d6c88
https://doi.org/10.17235/reed.2020.6857/2020
https://doi.org/10.17235/reed.2020.6857/2020